Pipeline Update: OD-002 CTA Filing on Track for H2 2026, Detailed OD-001 Phase 2a Results
ODTX sits 79% above its 52-week low of $15.1.
Summary
Odyssey Therapeutics released an updated corporate presentation detailing new pipeline milestones, including an OD-002 CTA filing in H2 2026 and a new OD-004 program, alongside updated OD-001 Phase 2a efficacy data.
Key Events · Product Development and Regulatory · ODTX
-
OD-002 CTA Filing Set for H2 2026
A Clinical Trial Application for OD-002, an SLC15A4 inhibitor, will be filed in H2 2026. Phase 1/2 initiation is expected in H1 2027, with Phase 2a readouts in H2 2028.
-
New OD-004 Program Disclosed
The presentation reveals OD-004, a TSLP/IL-33 protein targeting COPD and asthma, expanding the pipeline to four clinical-stage or IND-enabling programs.
-
OD-001 Phase 2a Data Updated
Consolidated Phase 2a data (n=49) show 27% clinical remission, 47% endoscopic improvement, and 61% symptomatic remission in moderate-to-severe UC patients. Among remitters, 62% achieved HEMI.
-
OD-002 Preclinical Profile Detailed
OD-002 demonstrates potency below 10 nM and selectivity greater than 1,000x over TLR3/STING/SLC15A1-3. The projected human dose is once-daily 18 mg, with composition of matter IP extending to 2046.
Analysis · ODTX · Life Sciences
An updated corporate presentation from Odyssey Therapeutics reveals new clinical milestones and preclinical data across its pipeline. The company confirms that OD-002, an SLC15A4 inhibitor, will file a Clinical Trial Application in H2 2026, with Phase 1/2 initiation expected in H1 2027. A new program, OD-004, targets TSLP/IL-33 for COPD and asthma. Updated Phase 2a data for OD-001 in moderate-to-severe ulcerative colitis show a 27% clinical remission rate, with 62% of remitters achieving histologic endoscopic mucosal improvement. With $433M in cash and runway into H2 2028, this update is meaningful for a $1.3B biotech with multiple near-term catalysts.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ODTX was trading at $26.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $15.10 to $29.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.